Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
May 29, 2008
Glaxo's Promacta Hits a Snag with the FDA
Analysis of: FDA says Glaxo drug fails to control bleeding | seattletimes.nwsource.com
Author: GLG Expert Contributor
Apparently, the FDA was not impressed enough with the data for Promacta (eltrombopag) for the treatment of ITP, a common and potentially serious auto-immune bleeding disorder involving platelets.  Citing a lack of "robust evidence" from several studies, the FDA will be seeking further opinions...
May 27, 2008
Revlimid (Celgene) in CLL- not a bad addition in our therapeutic algorithm
Analysis of: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
Revlimid has activity in Chronic Lymphatic Leukemia (CLL) in addition to myeloma and myelodysplasia.
May 27, 2008
So much for non-invasive surgery in prostate cancer
Analysis of: Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com
Author: GLG Expert Contributor
Higher recurrance rate???!!!
May 27, 2008
Genentech, Schering-Plough,,Avant Immunotherapeutics. & Pfizer all helping with "brain cancer" therapy.
Analysis of: Hints of Progress in Drugs Treating Brain Cancer | www.nytimes.com
Author: GLG Expert Contributor
     While no slam dunk cures are noted, drugs such as Avastin (Genentech), Temodar (Schering-Plough) &  Avant/Pfizer  vaccines  are making an impact on  "Brain Cancer"  survival.
May 22, 2008
Erbitux: Alot remains to be determined re: its place in NSCLCA therapy
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: GLG Expert Contributor
" Conclusions: Cetuximab does not appear to add to treatment efficacy when combined with gemcitabine and docetaxel in advanced NSCLC. A high rate of severe cetuximab HSRs necessitated trial closure at our Nashville site." Not very promising.
May 20, 2008
Chinese Generics?? You must be kidding!
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: GLG Expert Contributor
Low cost generics to be produced in China will lower drug costs.
May 20, 2008
Global Cancer Market: room for further growth!
Analysis of: Global market expected to drive cancer drug growth | www.therapeuticsdaily.com
Author: GLG Expert Contributor
As world economies improve more money will be spent globally on cancer care expanding potential markets
May 19, 2008
The gods giveth and then takith away- Go figure.....
Analysis of: First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations | jco.ascopubs.org
Author: GLG Expert Contributor
Two papers, the one above, and http://jco.ascopubs.org/cgi/content/full/26/15/2450 reveal somewhat conflicting data on AstraZeneca's Iressa that was until now on the "back burner" due to Genentech's Tarceva, that had better response data than Iressa in separate trials On one hand the first paper points...
May 19, 2008
Alimta (Lilly): YES!!!!
Analysis of: Lilly Drug Shown to Slow Lung Cancer | online.wsj.com
Author: GLG Expert Contributor
That Alimta can be effectively used after other chemotherapy in non small cell lung cancer (NSCLC) as a maintenance agent!
May 15, 2008
Novo Nordisk: Good try but recombinant activated factor VII did not reach its goal in hemorrhagic stoke
Analysis of: Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage | content.nejm.org
Author: GLG Expert Contributor
"In summary, rFVIIa reduced hematoma growth but did not reduce the rate of death or severe disability after intracerebral hemorrhage."

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to 90 of 450

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T13:45:17.613